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Abstract
This review summarises the new insights into the physiology of perioperative fluid therapy and analyses recent 
studies of the safety of the use of HES solutions in the fluid management of critically ill patients. This analysis reveals 
a number of methodological issues in the three major studies that have initiated the recommendation of the Euro-
pean Medicine Agency to ban hydroxyethyl starches from clinical practice. It is concluded that, when used in the 
proper indication, and taking into account the recommended doses, hydroxyethyl starches continue to have a place 
in perioperative fluid management.
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All things are poison, and nothing is without poison; only 
the dose permits something not to be poisonous
Paracelsus (1493–1541)
About 230 million patients undergo surgery each year. 
Reported mortality rates for elective non-cardiac surgery 
range between 1 and 4% [1, 2]. For many years there has 
been great interest in the development of strategies that 
may help to reduce perioperative morbidity and mortality 
[3, 4]. An important part of this so-called Enhanced Recovery 
After Surgery (ERAS) strategy relates to perioperative fluid 
management.
Initially, no clear distinction was made between the 
different types of fluids used for perioperative fluid manage-
ment. But during the last decade, a clear differentiation has 
been established between crystalloid substitution of extra-
cellular losses and stabilisation and optimisation of cardiac 
preload [5−7]. In the perioperative setting, a goal-directed 
approach to the latter has been shown to reduce morbid-
ity [8] and has been implemented in the British Consensus 
Guidelines on Intravenous Fluid Therapy for Adult Surgical 
Patients (GIFTASUP) [9].
In recent years, a number of publications have warned 
against the potential adverse effects of long-term use of 
hydroxyethyl starches (HES) in high cumulative doses, es-
pecially in septic patients. Although the clinical implications 
of such reports are controversial and discussion among 
experts is ongoing [10−13], on 14 June 2013 the risk assess-
ment committee of the European Medicines Agency (EMA) 
recommended suspending marketing authorisations for 
HES for all indications [14]. After extensive discussions, this 
recommendation was adapted later that year to say: “HES 
solutions must no longer be used to treat patients with 
sepsis (bacterial infection in the blood) or burn injuries or 
critically ill patients because of an increased risk of kidney 
injury and mortality. HES solutions may continue to be used 
in patients to treat hypovolaemia (low blood volume) caused 
by acute (sudden) blood loss, where treatment with alterna-
tive infusion solutions known as ‘crystalloids’ alone are not 
considered to be sufficient” [15]. 
The present review aims to summarise the new insights 
into the physiology of perioperative fluid therapy and to 
critically analyse recent studies of the safety of the use of HES 
solutions in the fluid management of critically ill patients.
PHYSIOLOGY OF PERIOPERATIvE FLUID LOSS
In normal conditions, about two-thirds of the total body 
water content is located intracellularly. The remainder is 
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located extracellularly, of which about 80% is located in the 
interstitial compartment and the remaining 20% in the in-
travascular compartment. Both latter subcompartments are 
separated by the vascular barrier. In normal conditions, this 
barrier retains the macromolecules within the intravascular 
space but it is freely permeable to water and electrolytes. For 
this reason, administration of isotonic crystalloids during the 
resuscitation of a bleeding patient will result in an even dis-
tribution of the infused amount over the entire extracellular 
space, which is 20% intravascular and 80% interstitial [16].
A normal healthy vascular endothelium is coated by 
the endothelial glycocalix. This layer, together with the en-
dothelial cells, constitutes a sort of double barrier both of 
which oppose unlimited extravasation [17]. In addition to 
its role as physiological endothelial permeability barrier, it 
prevents leucocyte and platelet adhesion, thereby mitigat-
ing inflammation and tissue oedema [6].
Fluid shifting out of the intravascular space does nor-
mally not occur at a body core temperature of between 
33 and 37°C. Below 30°C, a significant decrease in plasma 
volume is observed, accompanied by a decrease in central 
venous pressure, an increase in pulmonary and systemic 
vascular resistance, and an increase in haematocrit [18]. As 
a consequence, the phenomenon of fluid shifting should 
not be a common intraoperative problem in noncardiac 
surgery. Nevertheless, fluid shifting is a commonly seen 
phenomenon during and after surgical procedures. Perio-
perative weight gain is considered to be a reliable marker of 
fluid storage outside the vascular compartment. It has been 
shown that this weight gain is strongly related to patient 
mortality [19]. Other studies have confirmed that aggres-
sive crystalloid infusion leading to a positive fluid balance is 
associated with poor postoperative outcomes such as pro-
longed ventilator dependency and intensive care unit stay, 
and increased mortality [20, 21]. These observations were 
the start for a multitude of randomised trials comparing 
liberal fluid therapy to more restricted fluid administration 
strategies. An important consideration with these studies 
however is that both the restrictive and the liberal fluid 
regimens are ill-defined, and that methodology is very het-
erogenous, making global evidence-based recommenda-
tions difficult [22]. Nevertheless, the majority of systematic 
reviews and meta-analyses indicate that the application of 
a goal-directed therapy is associated with better outcomes 
than a liberal fluid strategy [23, 24]. Goal-directed therapy 
implies that the amount of volume to be administered is 
assessed based on the analysis of specific variables. It is 
now widely accepted that urine output, pressure correlates 
of volume status, and other static variables are unreliable 
to assess the intravascular volume status and fluid need of 
patients. Instead dynamic variables such as pulse pressure 
variation and stroke volume variation may give a more reli-
able idea of the patient’s intravascular volume status [25]. 
However, a number of drawbacks need to be taken into ac-
count for these indices for the assessment of volume status 
and fluid responsiveness [26, 27].
PERIOPERATIvE FLUID HANDLING
From a physiological point of view, perioperative fluid 
administration basically needs to replace two entirely differ-
ent kinds of losses: (i) losses occurring all the time (primarily 
urine production and insensible perspiration); and (ii) losses 
occurring exclusively during trauma and surgery (mainly 
blood losses).
losses occUrring at all time
The extent of these losses may differ from normal both 
in the perioperative setting and in the critically ill patient. 
However, there are some common beliefs with regard to 
these losses that need to be put in perspective. 
There is a general tendency to overestimate preopera-
tive fluid deficit and perioperative insensible losses. This 
results in a liberal fluid administration strategy with recom-
mendations of basal crystalloid infusion rates up to 15 mL 
kg-1 h-1 as a perioperative standard measure for major in-
tra-abdominal surgery [28]. It is obvious that such strategies 
may easily end up with positive fluid balances of up to 10 L. 
The observation of a concomitant parallel perioperative 
increase in body weight however suggests that the contribu-
tion of insensible perspiration to perioperative fluid needs 
should be minimal [6]. Direct measurements of insensible 
perspiration have indeed indicated that the latter is highly 
overestimated and that the basal evaporation of approxi-
mately 0.5 mL kg-1 h-1 in the awake adult increases at the 
most to 1 mL kg-1 h-1 during large abdominal surgery even 
with maximal bowel exposure [29]. In addition, also the 
impact of preoperative fasting is seriously overestimated. 
It has indeed been demonstrated that even after a period 
of extended fasting, intravascular blood volume seems to 
remain within normal ranges [30]. Moreover, the current 
fasting guidelines have substantially decreased the preop-
erative period of fasting and also the routine use of bowel 
preparation is now questioned.
Another point of interest is the practice of compensation 
by fluid administration of the decreased circulatory state 
during and after induction of general or neuraxial anaesthe-
sia. It should be noted that this transient decrease actually 
constitutes a state of relative hypovolemia due to a decrease 
of sympathetic tone. So treatment should consist of restor-
ing sympathetic tone with small doses of vasopressors, 
instead of the administration of various amounts of fluids.
Finally, perioperative fluid management still is frequent-
ly based on urine output measurements, where an output 
of 0.5 mL kg-1 h-1 is considered to be a minimum. However, 
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urine output may be a very poor and unreliable indica-
tor of circulatory filling status in the perioperative period. 
Indeed, the perioperative period should be considered as 
a period of general stress and the body reacts accordingly 
by — among others — the release of antidiuretic hormone 
and the activation of the renin-angiotensin-aldosterone axis 
resulting in sodium and water retention. As a consequence, 
decreased urinary output in the perioperative phase merely 
constitutes a physiological response to surgical trauma and 
is not necessarily an indication of impaired circulating vol-
ume or imminent acute renal failure.
Losses related to urine output and perspiration insensi-
bilis affect the entire extracellular space, which includes the 
intravascular plus the interstitial space. This loss does not 
normally lead to a decrease in the colloid osmotic force of 
the intravascular space. In normal conditions, these are re-
placed by the absorption of colloid-free fluid and electrolytes 
from the gastrointestinal tract. In the fasted patients, this 
compensation mechanism may fail and has to be replaced 
artificially. Theoretically, the best solution is the administra-
tion of crystalloids, ideally in a balanced form, to prevent 
acid-base disorders. Because crystalloids are not retained 
by the vascular barrier they are homogenously distributed 
within the entire extracellular compartment. There is no 
place for colloids to compensate for these fluid losses since 
they will primarily compensate only the intravascular com-
partment. However, it is important to note that the volume 
effects of colloids have been shown to be context-sensitive. 
A simultaneous infusion of iso-oncotic colloids during acute 
bleeding has a volume effect of more than 90%. In contrast, 
in a normovolemic patient, approximately 60% of the same 
preparation will leave the vasculature towards the interstitial 
space within minutes. The reason for this phenomenon is 
a hypervolemia-related impairment of the vascular bar-
rier functioning [31]. Volume effects of colloids therefore 
depend on the context, which is the volume and hydration 
state of the patient [32]. As a consequence, treating relative 
hypovolemia secondary to vasodilation with colloids carries 
the inherent risk of later inducing relative hypervolemia with 
pulmonary oedema once the vascular tone restores at the 
end of surgery and anaesthesia. 
losses occUrring exclUsively  
dUring traUma and sUrgery
This type of loss induces primarily an isolated intravas-
cular deficit, including losses of all blood components. In 
substituting acute blood losses there is no physiological 
correlate that can be mimicked. The primary goal to account 
for these losses is to maintain the circulatory volume in or-
der to maintain haemodynamic stability. Theoretically, this 
could be achieved by the substitution of the blood elements 
and the plasma components including the clotting fac-
tors. However, because of infection and incompatibility risks, 
and financial and logistical implications, the administration 
of blood products and plasma components will mainly be 
driven to correct specific deficits in these components.
Since the primary goal of fluid replacement with these 
losses is a prompt and longlasting restoration of the intravas-
cular volume, the ideal solution should have a good volume 
expansion effect and preferably have no side effects. Table 
1 summarises the properties of the different available solu-
tions. Since isotonic crystalloids distribute within the whole 
extracellular compartment, about 80% of the amount of 
fluid will leave the intravascular compartment within a short 
time. As a consequence, this type of fluid is inappropriate 
when the goal is to expand specifically the intravascular 
space. The recommendation [33] and still widely applied 
strategy to substitute the first 1,000 mL of blood loss with 
a three- or fourfold dose of isotonic crystalloids has no 
physiological rationale. Similarly, there are no arguments 
to increase crystalloid infusion rates when patients seem to 
be clinically hypovolemic during surgery despite an intact 
extracellular fluid balance [6]. Colloids, on the other hand, 
remain intravascularly, and in the specific setting of acute 
bleeding have a volume effect of more than 90% [25]. 
PERIOPERATIvE FLUID SHIFTS
Fluid shifting towards the interstitial space can be di-
vided into two types. Type 1 is the physiological shift which 
occurs at all times. It refers to an almost colloid-free shift of 
fluid and electrolytes out of the intravascular space. This type 
of shift occurs even when the vascular barrier is intact. Type 2, 
on the other hand refers to a pathological fluid shift in which 
fluid containing protein close to the plasma concentration 
crosses a functionally altered vascular barrier. This type of 
fluid shift occurs with alteration of the endothelial glycocalix 
and the endothelial cells by, for instance, mechanical stress, 
endotoxin exposure, and ischaemia-reperfusion injury or 
inflammation, but may also occur in the context of acute 
hypervolemia [6].
Part of the perioperative fluid management strategies 
should be directed towards minimising the extent of both 
types of fluid shifting. Minimising type 1 shifting implies 
the use of crystalloids only to replace urine production 
and insensible perspiration and use iso-oncotic colloids for 
replacement of acute blood loss. Minimising type 2 shift-
ing implies avoiding any cause of endothelial barrier dam-
age. Several approaches can be considered [6] but a key 
element is to carefully maintain intravascular volume and 
avoid any hypervolemic peak. Once a type 2 shifting has 
occurred, this means that there is a leakage of protein rich 
fluid. Causal treatment of the intravascular hypovolemia due 
to a protein-rich type 2 shift should aim at restoring as much 
as possible the intravascular colloid osmotic force, hence the 
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administration of colloids. Using crystalloids in this situation 
will only aggravate the clinical picture by a massive increase 
of the physiological type 1 shift, which will further increase 
the interstitial load.
HES: A DEBATE OR KILLING OF A MOLECULE?
When the decision is taken — based on the physiologi-
cal arguments elaborated above — to administer colloids in 
a fluid administration strategy, the choice of agent should 
be based on considerations of volume expansion vs safety 
concerns.
While the immediate plasma-extending properties are 
similar between gelatins and HES solutions, the latter tend 
to remain longer in the circulation [34−37]. In addition, the 
incidence of allergic reactions, though very small, has been 
reported to be higher with gelatins than with HES solutions 
[38, 39]. Administration of the older HES preparations with 
higher molecular weight has been associated with an in-
creased blood loss and need for blood transfusion, but this 
phenomenon seems to be absent with the newer prepara-
tions with lower molecular weight [36].
As a consequence, according to a recent international 
cross-sectional study in 391 intensive care units, HES prepa-
rations seemed to be fairly popular as resuscitation fluid in 
critically ill adults [40].
Meanwhile, a number of studies have been published 
that have started to question the safety of the use of HES 
preparations concerning adverse effects on mortality but 
also on morbidity and more specifically increased renal 
dysfunction and failure. These concerns have resulted in 
the negative advice given by the EMA with regard to the 
use of HES solutions in patient care [14, 15]. Despite the fact 
that these different studies were all published in prestigious 
journals, they all contain some methodological flaws that 
hamper the drawing of conclusions and in fact bring into 
question the recommendations concerning the banning of 
HES solutions from clinical practice.
There is an important consideration to be made with 
regard to the issue of fluid resuscitation, which is that fail-
ure to early haemodynamically stabilise patients in acute 
shock makes it very difficult to compensate for this fail-
ure at a later stage [41]. In haemodynamic resuscitation, 
two phases need to be distinguished: an initial (six hours) 
resuscitation phase which is followed by a maintenance 
phase. During the initial phase, volume therapy is an im-
portant part of an outcome-relevant causal therapy. During 
the maintenance phase, fluid therapy is only one measure 
within a multifactorial supportive strategy, and therefore 
any causal relationship between this single strategy and 
patient outcome is extremely hazardous [42]. This needs to 
be taken into account when evaluating the different studies 
that have resulted in the EMA recommendations with regard 
to HES solutions.
visep stUdy
The VISEP (volume substitution and insulin therapy in 
severe sepsis) compared the use of Ringer’s lactate to that 
of 10% HES 200/0.5 for volume replacement in 537 septic 
patients [43]. The colloid-treated patient group showed 
an increased incidence of renal failure and a ‘trend’ (P = 0.09) 
towards higher 90-day mortality. However, it should be 
noted that in this trial, the start of the study treatment was 
delayed for up to 24 hrs after diagnosis of severe sepsis. This 
implies that, for the majority of patients, at this time initial 
stabilisation of haemodynamics was already completed. 
Indeed, when looking at the baseline values at randomisa-
tion, it appears that all target values for resuscitation, as 
defined by the Surviving Sepsis Campaign Guidelines [44], 
were already reached before randomisation. The result is 
that 58% of the patients in the crystalloid group who had 
already successfully been stabilised haemodynamically 
before randomisation did receive up to 1 L HES for initial 
resuscitation (remarkably, a further 33% in this group re-
ceived colloids during the trial). Conversely, the patients 
in the colloid group received an outdated hyperoncotic 
solution over a prolonged period of time in the absence of 
a proper (physiological) indication and in daily cumulative 
doses beyond the recommendations. 
This point is important, because apparently the sub-
group of patients who received the HES solution in daily 
amounts within the recommended range showed a lower 
mortality than the crystalloid group.
6s stUdy
The 6S (Scandinavian Starch for Severe Sepsis/Septic 
Shock) trial compared the use of Ringer’s acetate to the 
administration of 6% HES 130/0.42 for fluid resuscitation in 
800 septic patients [45]. The authors observed an increased 
need for renal replacement therapy and a significantly high-
er 90-day mortality in the patients randomised to the HES 
group. However, also in this study, patients were once again 
only randomised up to 24 hrs after the diagnosis of sepsis 
or septic shock. The consequence of this approach was 
that — similar to VISEP — 60% of patients in the crystalloid 
group had already received up to 1 L of colloid for initial 
resuscitation and that in the colloid group the majority 
of patients were already stabilised with target values bet-
ter than those of the Surviving Sepsis Guidelines [44]. This 
implies that, also in this study, the patients randomised to 
the HES group were, once again, tested for a non-indicated 
drug compared to the rational and well established strategy 
for fluid maintenance with crystalloids in stable patients. In 
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addition, at study onset 36% of the randomised patients 
had renal failure, which is an established contraindication 
for HES administration. Finally, 32% of the patients allocated 
to the crystalloid group received colloids during the trial and 
in 216 patients (27%) the trial fluid was discontinued during 
the study. Despite these methodological issues, all patients 
were included into the follow-up. Of note, the RIFLE score, 
which allows for objective reporting of the grade of renal 
function impairment and failure, is only reported in the 
supplement. Interestingly, there seems to be no significant 
difference between groups [42]. It is therefore impossible to 
grasp the potential implications on outcome when the pic-
ture is blurred by a multitude of methodological issues [42].
chest stUdy
The CHEST (Crystalloid versus HydroxyEthyl Starch Trial) 
randomised 7,000 patients at mean 11 hours after admis-
sion on the intensive care unit, to receive either saline or 
6% HES 130/0.4 for fluid resuscitation [46]. No difference 
was observed between groups in 90-day mortality or renal 
function according to the RIFLE criteria. However, the au-
thors reported an increased incidence in renal replacement 
therapy. It is unclear why a group of patients with better 
renal function nevertheless had a higher need for renal 
replacement therapy. In the absence of well-defined criteria 
for the use of renal replacement therapy, it is very likely that 
the higher incidence of renal replacement therapy simply re-
flects the situation that more patients received this therapy 
but that this by no means implies that this therapy was in-
deed required. Instead, an independent analysis of the data 
even indicates that due to an improved kidney function and 
no differences in renal replacement therapy, CHEST shows 
an advantage over HES [42]. In addition, also in this study 
haemodynamic targets for initial fluid resuscitation were 
already met at the time of inclusion, suggesting haemody-
namic stability and no need for additional colloid therapy. 
Also, similar to the VISEP and 6S, 36% of patients had renal 
failure at randomisation and should have been excluded. 
Finally, 508 patients of the saline group had received HES 
prior to randomisation. Of note, 30% of the patients were 
septic and in this subgroup no difference in mortality, renal 
failure or need for renal replacement therapy was observed. 
HES: PUTTING THE FACTS TOGETHER
It seems therefore that of the three main papers that 
have questioned the safety of HES solutions in the fluid man-
agement of critically ill patients, one showed no relevant 
differences [46] and two suffered from major methodologi-
cal issues [43, 45]. These issues include treatment strategies 
not reflecting clinical reality, ignoring contraindications 
and maximum recommended daily doses, overinterpreta-
tion of results, and selective biased analysis of data [42]. It 
is also important to note that these three studies failed to 
address the initial resuscitation phase after the diagnosis of 
sepsis and septic shock. Actually, in all trials, colloids were 
administered to a majority of patients during this phase. As 
a consequence, one can only conclude that specifically in 
a group of patients treated with HES, the wrong fluid was ad-
ministered at the wrong time (after haemodynamic stabilisa-
tion crystalloids are to be administered) in an inappropriate 
amount (exceeding daily recommended doses) in the wrong 
patients (pre-existing acute renal failure at randomisation). 
In addition, the results of these trials — especially taking 
into account the abovementioned shortcomings — do not 
allow the provision of recommendations on the indications 
of these compounds in the setting of acute need for volume 
replacement. Indeed, when used in the proper indication 
as early stage resuscitation fluid, it has been shown that 
6% HES 130/0.4 could have a superior risk/benefit ratio and 
improved outcome compared to crystalloids [2, 47−51].
CONCLUSIONS
In the discussion about fluid management strategies, 
it is of prime importance that intravenous fluids should be 
treated as foreign substances that are introduced into the 
body. Therefore, their administration should be guided by 
the same concerns as the administration of drugs, taking 
into account strict indications and the necessary precau-
tions with respect to side effects and potential adverse 
reactions. It seems that the debate about the place of HES 
in the treatment of critically ill patients is blurred by a clash 
of strong opinions. It is therefore essential that currently 
available data is evaluated in an objective manner with 
respect to the underlying physiology and pathophysiol-
ogy of fluid treatment in various disease states [12]. Only 
in this way can evidence-based clinical recommendations 
be provided.  
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